Associate Professor Wilson Heriotis a vitreo-retinal specialist based in Melbourne, Australia and the director of Retinology Institute. After completing his general ophthalmic training in Melbourne, he investigated phototoxic retinal injury and choroidal neovascularization during a two-year Medical retinal research fellowship with Paul Henkind in New York. This was followed by a vitreoretinal surgical fellowship with Robert Machemer at Duke University also investigating RPE repair.
His current research projects include a translation to clinical care program for a new method of retinal detachment repair called Retinal Thermofusion funded by a USA Department of Defense Award. Another project with colleagues at the Department of Optometry and Vision Sciences and University of Melbourne measuring retinal capillary autoregulation changes in diabetic patients, which received a Bayer GOAP award in 2020. Associate Professor Heriot is also a principle investigator for a number of local and international clinical trials in areas of Diabetic Retinopathy and Age-related macular denegation.
- Associate Professor (Clinical), Ophthalmology, Department of Surgery, University of Melbourne
- Associate Professor (Clinical), Department of Optometry and Vision Sciences, University of Melbourne
- Principal Investigator in Vitreoretinal Research, Centre for Eye Research Australia
- Honorary Consultant Retinal Surgeon, Royal Children’s Hospital and Royal Women’s Hospital, Melbourne, Australia
- Medical Advisory Board member at Roche, Novartis and Bayer
“I see clinical medicine not only as an opportunity to help patients but also as a test bed for assessing the effectiveness of current management strategies and the improvements offered by new treatments. It is also an opportunity to consider how to do things better. I particularly love filling in gaps in our knowledge and identifying potentially better solutions.
Every patient has unique features that defines their individual response to therapy but, importantly, those features offer clues that can trigger the clinical insights necessary for a deeper understanding of disease. It is a very rewarding challenge to devise the optimised care strategy for each individual. We are always striving to be at the cutting edge and offer the best care for each patient.”